Search Results

CHOICE Postmarket Data Presented for Abbott's Carotid Stents and EPDs

October 10, 2013—The CHOICE trial of carotid artery stenting (CAS) in a postmarket setting was presented by Chris Metzger, MD, at a late-breaking trial session during the VIVA 2013: Vascular Interventional Advances conference, being held October 8–11 in Las Vegas, Nevada.

POWER PAD II Data Presented for AVS Pulse IVL System

November 4, 2025—Amplitude Vascular Systems (AVS) announced results from the first 95 patients treated in the POWER PAD II United States pivotal study for pulsatile intravascular lithotripsy (IVL) therapy.

AVS’s Pulse IVL POWER PAD II Pivotal Trial Begins Enrollment

October 15, 2024—Amplitude Vascular Systems (AVS), which is focused on treating severely calcified arterial disease, announced commencement of patient enrollment in the POWER PAD II United States pivotal trial of the company’s Pulse intravascular lithotripsy (IVL) system for pulsatile intravascular lithotripsy therapy.

InspireMD’s CGuard EPS to Treat Carotid Artery Disease Evaluated in C-Guardian Trial in the United States

July 23, 2021—InspireMD, Inc. announced the initiation of enrollment and the successful completion of the first cases of the company’s United States C-Guardian trial of the company’s CGuard embolic prevention stent system (EPS) for the treatment of carotid artery disease (CAD) and stroke prevention.

AVS Receives IDE for Pulse IVL System’s POWER PAD II Pivotal Trial

June 6, 2024—Amplitude Vascular Systems (AVS), which is focused on treating severely calcified arterial disease, announced that it has received an investigational device exemption from the FDA to begin its pivotal trial of its Pulse device for pulsatile intravascular lithotripsy (IVL) therapy.

InspireMD’s CGuard Prime Carotid Stent System Launched in United States

July 9, 2025—InspireMD, Inc. announced the commercial launch of the CGuard Prime carotid stent system in the United States.

AVS Raises Financing to Support Pulse IVL System Launch in the United States

January 28, 2025—Amplitude Vascular Systems (AVS), developer of the Pulse intravascular lithotripsy (PIVL) platform for the treatment of severely calcified arterial disease, announced that it has completed a Series B round of financing of $36 million.